secwatch.observer — SEC 8-K summary
======================================

Issuer:     Twist Bioscience Corp (TWST)
CIK:        0001581280
Form:       8-K
Filed at:   2023-08-04T23:59:59+00:00
Accession:  0001628280-23-027406
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Twist Bioscience reports Q3 FY2023 revenue of $63.7M (up 14% YoY); CFO to transition to new role
--------------------------------------------------------------------------------

- Revenue $63.7M, up 14% YoY from $56.1M; net loss $57.4M ($1.01/share) vs $60.5M prior year.
- CFO James Thorburn will transition to a new commercial/scaling role once successor is hired; search underway.
- Cash and investments $357.1M at June 30, 2023; shipped products to ~2,200 customers.
- Launched RNA sequencing portfolio; entered collaboration with Cancer Research Horizons.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1581280/000162828023027406/0001628280-23-027406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1581280/000162828023027406/twist-20230803.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-027406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer